Mar 10
Biotech2050 Podcast: Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms
| Over the past decade, CAR-T therapies have demonstrated curative potential, while also underscoring how complexity, cost, and infrastructure can limit the number of patients who can be treated.
In this episode of the Biotech2050 podcast, Artiva’s CEO Fred Aslan discusses how lessons from the first generation of CAR-T therapies are shaping new approaches in autoimmune disease, an area where the need for more durable treatment options remains significant. The conversation explores what CAR-T has revealed about the depth of immune intervention required to modify disease, and how Artiva is applying those insights as a clinical-stage company advancing AlloNK® in autoimmune disease, with a focus on scalability, real-world applicability, and patient access. |